EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells

Iñaki Ortiz de Landazuri iD, Aina Oliver-Caldés, Marta Español-Rego, Cristina Agulló, María Teresa Contreras, Aintzane Zabaleta, Noemí Puig, Valentín Cabañas, Verónica González-Calle, Inés Zugasti, Susana Inogés, Paula Rodríguez Otero iD und 22 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Iñaki Ortiz de Landazuri und 33 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Mass Spectrometry. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: RICORS-TERAV, La Caixa Foundation, Centro de Investigación Biomédica en Red de Cáncer CIBERONC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell therapies have increased the patients with relapsed/refractory multiple myeloma (RRMM) in whom standard electrophoretic techniques fail to detect the M‐protein. Quantitative immunoprecipitation mass spectrometry (QIP‐MS) can accurately measure serum M‐protein with high sensitivity, and identify interferences caused by therapeutic monoclonal antibodies. Here, we investigate the outcome of QIP‐MS in 33 patients treated with the academic BCMA‐directed CAR T‐cell ARI0002h (Cesnicabtagene Autoleucel). QIP‐MS offered more detailed insights than serum immunofixation (sIFE), identifying glycosylated M‐proteins and minor additional peaks. Moreover, the potential interferences owing to daratumumab or tocilizumab treatments were successfully detected. When analysing different assay platforms during patient's monitoring after ARI0002h administration, we observed that QIP‐MS showed a high global concordance (78.8%) with sIFE, whereas it was only moderate (55.6%) with bone marrow (BM)‐based next‐generation flow cytometry (NGF). Furthermore, QIP‐MS consistently demonstrated the lowest negativity rate across the different timepoints (27.3% vs. 60.0% in months 1 and 12, respectively). Patients with QIP‐MS(+)/BM‐based NGF(−) showed a non‐significant shorter median progression free survival than those with QIP‐MS(−)/BM‐based NGF(−). In summary, we show the first experience to our knowledge demonstrating that QIP‐MS could be particularly useful as a non‐invasive technique when evaluating response after CAR T‐cell treatment in MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveMass SpectrometryHumansMaleFemaleMiddle AgedAgedReceptors, Chimeric AntigenMyeloma ProteinsAdultAntibodies, Monoclonal, HumanizedB-Cell Maturation Antigen

Stichwörter der Autor:innen

CAR T‐cell therapymass spectrometrymultiple myeloma

Substanzen

Receptors, Chimeric AntigenMyeloma ProteinsAntibodies, Monoclonal, HumanizedB-Cell Maturation Antigenmultiple myeloma M-proteins

Autor:innen und Institutionen

  • Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Instituto Universitario de Biología Molecular y Celular del Cáncer (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • Cancer Center Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
  • Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Universidad de Murcia, Murcia, Spain.
  • Instituto de Investigación Sanitaria, Fundación Jiménez Díaz, Madrid, Spain.

ORCID-Profile: Iñaki Ortiz de Landazuri, Paula Rodríguez Otero, Laura Rosiñol, María Victoria Mateos, Carlos Fernández de Larrea

Förderung

  • RICORS-TERAV
  • La Caixa Foundation
  • Centro de Investigación Biomédica en Red de Cáncer CIBERONC
  • Instituto de Salud Carlos III (cofounded by the EU), Spanish Ministry of Health
  • Fundación Científica Asociación Española contra el Cáncer
  • AGAUR, Generalitat de Catalunya
  • Instituto de Salud Carlos III
  • Agència de Gestió d'Ajuts Universitaris i de Recerca

Zitieren

APA

Ortiz de Landazuri, I., Oliver-Caldés, A., Español-Rego, M., Agulló, C., Contreras, M. T., Zabaleta, A., Puig, N., Cabañas, V., González-Calle, V., Zugasti, I., Inogés, S., Rodríguez Otero, P., Martin-Antonio, B., Reguera, J. L., López-Diaz de Cerio, A., Aróstegui, J. I., Uribe-Herranz, M., Benítez-Ribas, D., Rodríguez-Lobato, L. G., …, & Fernández de Larrea, C. (2024). Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells. British Journal of Haematology. https://doi.org/10.1111/bjh.19589

Vancouver

Ortiz de Landazuri I, Oliver-Caldés A, Español-Rego M, Agulló C, Contreras MT, Zabaleta A, et al. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells. British Journal of Haematology. 2024. doi:10.1111/bjh.19589

BibTeX
@article{OrtizdeLandazuri2024,
  author = {Ortiz de Landazuri, Iñaki and Oliver-Caldés, Aina and Español-Rego, Marta and Agulló, Cristina and Contreras, María Teresa and Zabaleta, Aintzane and Puig, Noemí and Cabañas, Valentín and González-Calle, Verónica and Zugasti, Inés and Inogés, Susana and Rodríguez Otero, Paula and Martin-Antonio, Beatriz and Reguera, Juan Luis and López-Diaz de Cerio, Ascensión and Aróstegui, Juan Ignacio and Uribe-Herranz, Mireia and Benítez-Ribas, Daniel and Rodríguez-Lobato, Luis Gerardo and González, Europa Azucena and Tovar, Natalia and Charry, Paola and Navarro, Sergio and Rosiñol, Laura and Tréboles, Karen and Mora, Génesis and Yagüe, Jordi and Moraleda, José María and Urbano-Ispizua, Álvaro and Mateos, María Victoria and Pascal, Mariona and Paiva, Bruno and Juan, Manel and Fernández de Larrea, Carlos},
  title = {Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19589}
}
Kostenlos starten →